MO
LCTX icon

McMillan Office’s Lineage Cell Therapeutics LCTX Stock Holding History

McMillan Office’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Hold
216,000
– – 0.03% 162
2026
Q1 		$341K Hold
216,000
– – 0.04% 143
2025
Q4 		$361K Buy
+216,000
New +$374K 0.04% 144

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

McMillan Office's LCTX Position: Q2 2026 in Review

McMillan Office held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 216,000 shares worth $283K. The position accounts for 0.03% of the portfolio, ranked #162.

McMillan Office first reported a position in LCTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $361K in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • McMillan Office held 216,000 shares of Lineage Cell Therapeutics worth $283K as of Q2 2026.
  • McMillan Office left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up 0.03% of McMillan Office's portfolio in Q2 2026, its #162 holding.
  • McMillan Office first reported a position in Lineage Cell Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • McMillan Office's Lineage Cell Therapeutics position peaked at $361K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.